Biologic and clinical relevance of an IFNG mRNA signature (IFNGS) and PD-L1 protein expression in tumor and immune cells in urothelial cancer (UC) patients (pts) treated with durvalumab (D).

Carlos Bais,Michael Kuziora,Chris Morehouse,Brandon W. Higgs,Rajiv Raja,Young Lee,Melissa de los Reyes,Marlon Rebelatto,Keith Steele,Xiaoping Jin,Li Shi,Fernanda Pilataxi,Yong Ben,Joyce Antal,Ashok Kumar Gupta,Koustubh Ranade

Biologic and clinical relevance of an IFNG mRNA signature (IFNGS) and PD-L1 protein expression in tumor and immune cells in urothelial cancer (UC) patients (pts) treated with durvalumab (D).

2017

Carlos Bais
Michael Kuziora
Chris Morehouse
Brandon W. Higgs
Rajiv Raja
Young Lee
Melissa de los Reyes
Marlon Rebelatto
Keith Steele
Xiaoping Jin
Li Shi
Fernanda Pilataxi
Yong Ben
Joyce Antal
Ashok Kumar Gupta
Koustubh Ranade

3037Background: PD-L1 can be induced by IFNG in tumor cells (TC) and immune cells (IC). TC PD-L1 expression prevalence in UC is low and the relevance of scoring TC (in addition to IC) is not fully ...

Keywords:

Immune system
PD-L1
Cancer
Protein expression
Pathology
Durvalumab
Medicine
Cancer research
Messenger RNA
Clinical significance
urothelial cancer
tumor cells

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations